secwatch.observer — SEC 8-K summary
======================================

Issuer:     Calidi Biotherapeutics, Inc. (CLDI)
CIK:        0001855485
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001493152-25-022349
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Calidi Biotherapeutics reports Q3 net loss of $5.2M; cash at $10.4M after $6.9M offering
--------------------------------------------------------------------------------

- Net loss $5.2M in Q3 2025; net loss attributable to shareholders $10.8M due to non-cash deemed dividend on warrants.
- Basic/diluted EPS loss $2.21 vs $7.75 prior year; cash $10.4M plus $0.2M restricted at Sep 30.
- Gross proceeds of $6.9M from underwritten public offering; total 2025 gross proceeds $23.0M.
- Presented CLD-401 preclinical data at SITC; new Scientific Advisory Board with four experts established.
- RedTail platform expands targeting capabilities and payloads; CLD-401 advancing to IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225022349/0001493152-25-022349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855485/000149315225022349/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer